Articolul precedent |
Articolul urmator |
439 2 |
Ultima descărcare din IBN: 2024-01-05 10:21 |
SM ISO690:2012 OBOROC, Sandu, BACHINSKY, N.G.. Pharmacological properties of direct factor Xa inhibitors. In: Cercetarea în biomedicină și sănătate: calitate, excelență și performanță, Ed. 1, 20-22 octombrie 2021, Chişinău. Chișinău, Republica Moldova: 2021, p. 43. ISBN 978-9975-82-223-7 (PDF).. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Cercetarea în biomedicină și sănătate: calitate, excelență și performanță 2021 | ||||||
Conferința "Cercetarea în biomedicină și sănătate: calitate, excelență și performanță" 1, Chişinău, Moldova, 20-22 octombrie 2021 | ||||||
|
||||||
Pag. 43-43 | ||||||
|
||||||
Descarcă PDF | ||||||
Rezumat | ||||||
Background. Severe and critical COVID-19 complications include embolism or pulmonary thrombosis, hypercoagulable state, following pathological mechanisms: activation of coagulation factors, decreased anticoagulant and fibrinolytic system. Anticoagulant therapy prevents thrombotic complications. Objective of the study. The selection and the analysis of the pharmacological properties of direct inhibitors of factor Xa and their mechanisms. Material and Methods. There were selected and analyzed the articles from the PubMed database according to the concepts “direct FXa inhibitors”, “anticoagulant activity”, “anti-inflammatory activity”, “antiviral activity”. Results. Direct FXa inhibitors (rivaroxaban) are small, selective and competitive molecules, that promote anticoagulant, anti-inflammatory and antiviral activity. Unlike heparins, they directly inhibit free and thrombus-binded FXa, with minimal bleeding risk. Antiviral activity reside in: blocking the viral entry of SARS-CoV-2 into the target cell, preventing the cleavage of the S protein; the inhibitory potential of TMPRSS2; the direct antiviral activity against a range of RNA and DNA viruses. Direct FXa antagonists inhibit the production of cytokines and molecules adhesion, decrease the adherence of leukocytes and prevent the onset of proinflammatory and profibrotic processes. Conclusion. Direct inhibitors of factor Xa decrease the states of hypercoagulability, but in relation to other classes of anticoagulants, have lower hemorrhage risk. They have the ability to inhibit the entry of the virus into cells, to prevent the onset of inflammatory and profibrotic processes. |
||||||
Cuvinte-cheie SARS-CoV-2, hypercoagulability, direct FXainhibitors, rivaroxaban, SARS-CoV-2, hipercoagulabilitate, inhibitori direcți FXa, rivaroxaban |
||||||
|